Sihuan Bio to acquire 80% of Changyuan Pharma for 160 million yuan at 115% premium
Sihuan Bio (000518.SZ) announced on September 23-24 it will acquire an 80% equity stake in Jilin Changyuan Pharmaceutical for 160 million yuan in cash, representing a 115.04% premium over net asset value. Changyuan Pharma, focused on drug R&D and production, will become a controlled subsidiary. The deal follows Sihuan Bio's earlier September announcement to acquire 65.6% of Zhongrun Pharma for 160 million yuan. Sihuan Bio, which has suffered five consecutive years of losses totaling over 300 million yuan, plans to finance the acquisition through a loan from China Merchants Bank.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Sihuan Bio to Acquire 80% Stake in Changyuan Pharma for 160 Million Yuan
Sihuan Biological (000518) announced on September 24 that it will acquire an 80% equity stake in Jilin Changyuan Pharmaceutical Co., Ltd. for 160 million yuan in cash. The transaction will make Changyuan Pharma a controlled subsidiary of Sihuan Bio, consolidating its financial results. Changyuan Pharma focuses on drug R&D, production, and sales, with key products including succinylated gelatin injection, which holds a high market share, and several exclusive traditional Chinese medicine (TCM) varieties such as Naoshuankang Capsules, Naotai Capsules, and Haidan Capsules. The acquisition aligns with Sihuan Bio's strategy to expand its product matrix and achieve a business layout combining biological products and chemical preparations. The company expects the deal to enhance profitability and core competitiveness. For the period from January to July 2026, Changyuan Pharma reported revenue of 54.855 million yuan and net profit of 13.096 million yuan.
Read sourceSihuan Bio to Acquire 80% Stake in Changyuan Pharma for 160 Million Yuan
On the evening of September 23, Sihuan Bio (四环生物) announced it plans to sign a share transfer agreement with Jiangxi Jixin Biotechnology Co., Ltd. to acquire 80% of the equity in Jilin Changyuan Pharmaceutical Co., Ltd. (长源药业) for a transaction price of 160 million yuan. Following the completion of the transaction, Changyuan Pharma will become a controlled subsidiary of Sihuan Bio. Changyuan Pharma is a pharmaceutical company focused on drug R&D, production, and sales, with main products including succinylated gelatin injection, Naoshuankang capsules, Naopei capsules, Haidan capsules, and hemorrhoid hemostasis pills. Sihuan Bio stated that the acquisition aligns with its current development strategy, allowing it to obtain competitive mature chemical preparations and multiple exclusive Chinese patent medicine varieties, enriching its product portfolio and supporting its business layout of 'biological products plus chemical preparations' in the pharmaceutical field.
Read sourceSihuan Bio to acquire 80% of Changyuan Pharma for 160 million yuan at 115% premium
Sihuan Bio, a Chinese biopharmaceutical and landscaping company that has suffered five consecutive years of losses totaling over 300 million yuan, announced it will acquire 80% of Jilin Changyuan Pharmaceutical for 160 million yuan, representing a 115.04% premium over net asset value. The target company, Changyuan Pharma, reported revenues of 121.46 million yuan in 2025 and 54.86 million yuan in the first seven months of 2026, with net profits of 33.94 million and 13.10 million respectively, though its operating cash flow turned negative in the 2026 period. The acquisition follows Sihuan Bio's earlier September announcement to acquire 65.6% of Zhongrun Pharma for 160 million yuan. Sihuan Bio states the deal aligns with its strategy to acquire competitive pharmaceutical products and boost profitability. However, the company's stock had been under delisting risk until May 2026 due to negative net profit and revenue below 300 million yuan in 2024, and its 2026 first-half net loss widened to 25.83 million yuan. The company plans to finance the acquisition through a loan from China Merchants Bank. The company warns of risks including goodwill impairment, integration challenges, and potential failure to complete regulatory procedures.
Read sourceShow 2 older updatesHide older updates
Sihuan Bio to Acquire 80% Stake in Changyuan Pharma for 160 Million Yuan
Beijing Business Today reports that Sihuan Bio (stock code 000518) announced on the evening of September 23 that it plans to sign a share transfer agreement with Jiangxi Jixin Biotechnology Co., Ltd. to acquire 80% of the equity in Jilin Changyuan Pharmaceutical Co., Ltd. for a transaction price of 160 million yuan. Following the completion of the transaction, Changyuan Pharma will become a controlled subsidiary of Sihuan Bio. According to the announcement, Changyuan Pharma is a pharmaceutical company focused on drug R&D, production, and sales, with main products including succinylated gelatin injection, Naokangshu capsules, Naotai capsules, Haidan capsules, and hemorrhoid hemostatic pills. Sihuan Bio stated that the acquisition aligns with its current development strategy, allowing it to obtain competitive mature chemical preparations and multiple exclusive Chinese patent medicine varieties, thereby enriching its product portfolio and facilitating its business layout in the pharmaceutical field combining 'biological products and chemical preparations.'
Read sourceSihuan Bio to Acquire 80% Stake in Changyuan Pharma for 160 Million Yuan
Sihuan Bio (000518.SZ) announced it will acquire an 80% equity stake in Jilin Changyuan Pharmaceutical Co., Ltd. for 160 million yuan in cash. The transaction will make Changyuan Pharma a controlled subsidiary of Sihuan Bio. Changyuan Pharma is a pharmaceutical company focused on R&D, production, and sales, with products including succinylated gelatin injection, Naoshuankang capsules, Naotai capsules, Haidan capsules, and hemorrhoid hemostatic pills. Its core product, succinylated gelatin injection, holds a high market share and strong competitiveness. Additionally, Naoshuankang capsules, Naotai capsules, and Haidan capsules are exclusive varieties, while hemorrhoid hemostatic pills and Yanghuo Sanqi tablets are exclusive dosage forms with market potential. Sihuan Bio stated the acquisition aligns with its development strategy, adding mature chemical preparations and multiple exclusive Chinese patent medicines to enrich its product matrix and advance its 'biological products + chemical preparations' business layout in the pharmaceutical field.
Read source